Crossref
The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC
AME Clinical Trials Review · 2024
DOI: 10.21037/actr-23-33 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2024. Verfasst von Takahiro Karasaki.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Karasaki, T. (2024). The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC. AME Clinical Trials Review. https://doi.org/10.21037/actr-23-33
Vancouver
Karasaki T. The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC. AME Clinical Trials Review. 2024. doi:10.21037/actr-23-33
BibTeX
@article{Karasaki2024,
author = {Karasaki, Takahiro},
title = {The third-generation EGFR TKI osimertinib could be a promising neoadjuvant therapy in patients with resectable EGFR-mutant NSCLC},
journal = {AME Clinical Trials Review},
year = {2024},
doi = {10.21037/actr-23-33}
}
EUVIMED